Dr. Richard Larivière is a professor in the Department of Medicine at Laval University, and a researcher within the Endocrinology and Nephrology axis of the CHU of Quebec Research Centre. He is also Director of Master’s and PhD programs in Clinical and Biomedical Sciences of the Faculty of Medicine at Laval University. Following his doctoral studies in Clinical Sciences (cardiovascular pharmacology) at the Université de Montréal, and postdoctoral studies in molecular endocrinology at McGill University, Dr. Larivière established himself as a professor-researcher in nephrology and hypertension at L’Hôtel-Dieu de Québec. He is an active member of the Amgen-Laval University Research Chair in Nephrology, a multidisciplinary group of fundamentalist and clinical researchers.
The main objective of Dr. Larivière’s research is to better define the mechanisms of arterial hypertension and remodeling of the blood vessel wall. More specifically, he studies the role of endothelial dysfunction, that is, factors derived from the vascular endothelium in the pathogenesis of arterial hypertension, vascular and renal damage in the case of chronic renal failure, and aging. Over the years, he has demonstrated that an imbalance in endothelial production of vasoconstrictor and vasodilator factors, as well as pro-inflammatory factors, contributes significantly to the increase of arterial pressure and rigidity by stimulating, among other things, hypertrophic remodeling and calcification of the blood vessel wall. He has also demonstrated that endothelial dysfunction can be modulated by various endocrine factors and pharmacological agents, including certain drugs. Dr. Larivière’s research uses a variety of experimental models and human tissue libraries.
10, rue McMahon
Canada G1R 2J6
Data not available
Thromboxane blockade reduces blood pressure and progression of renal failure independent of endothelin-1 in uremic rats.Journal Article
Prostaglandins Leukot Essent Fatty Acids, 71 (2), pp. 103-9, 2004, ISSN: 0952-3278.
Blood pressure-independent effect of angiotensin AT1 receptor blockade on renal endothelin-1 production in hypertensive uremic rats.Journal Article
J Hypertens, 19 (8), pp. 1479-87, 2001, ISSN: 0263-6352.
Supplementation with a low dose of L-arginine reduces blood pressure and endothelin-1 production in hypertensive uraemic rats.Journal Article
Nephrol Dial Transplant, 16 (4), pp. 746-54, 2001, ISSN: 0931-0509.
Renal and vascular effects of chronic nitric oxide synthase inhibition: involvement of endothelin 1 and angiotensin II.Journal Article
Can J Physiol Pharmacol, 77 (1), pp. 8-16, 1999, ISSN: 0008-4212.
Increased immunoreactive endothelin-1 levels in blood vessels and glomeruli of rats with reduced renal mass.Journal Article
Kidney Blood Press Res, 20 (6), pp. 372-80, 1997, ISSN: 1420-4096.
- Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
- Proline hydroxylase inhibitors: linking HIF-1 to arterial calcification, Subvention, Fondation canadienne du rein, Subvention de soutien à la recherche biomédicale, from 2019-07-01 to 2021-06-30
- Rôle de la dysfonction endothéliale dans le remodelage et la calcification vasculaire en insuffisance rénale chronique, Subvention, Fondation de l'Université Laval, from 2016-04-01 to 2022-03-31